Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Average Target Price from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) have received an average rating of "Buy" from the seven research firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.00.

A number of equities analysts have recently issued reports on QNCX shares. D. Boral Capital reiterated a "buy" rating and issued a $4.00 price target on shares of Quince Therapeutics in a report on Friday, June 13th. Oppenheimer assumed coverage on shares of Quince Therapeutics in a research report on Monday, March 24th. They set an "outperform" rating and a $10.00 price target on the stock. Finally, Wall Street Zen cut shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors have recently modified their holdings of QNCX. Anfield Capital Management LLC acquired a new position in shares of Quince Therapeutics during the 4th quarter worth approximately $50,000. Virtu Financial LLC bought a new position in Quince Therapeutics in the fourth quarter valued at about $55,000. Two Sigma Investments LP acquired a new stake in shares of Quince Therapeutics in the fourth quarter valued at about $57,000. Intellectus Partners LLC acquired a new stake in Quince Therapeutics during the first quarter worth approximately $71,000. Finally, Northern Trust Corp grew its stake in Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company's stock valued at $94,000 after acquiring an additional 16,501 shares during the period. Institutional investors own 30.75% of the company's stock.

Quince Therapeutics Stock Performance

NASDAQ QNCX traded down $0.10 during mid-day trading on Thursday, reaching $1.50. 206,216 shares of the stock were exchanged, compared to its average volume of 302,376. The business's 50 day moving average is $1.12 and its 200-day moving average is $1.39. The company has a market capitalization of $68.21 million, a P/E ratio of -1.08 and a beta of 0.80. The company has a debt-to-equity ratio of 0.82, a quick ratio of 4.05 and a current ratio of 4.05. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, equities research analysts forecast that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.